A multi-institutional Clinical Core Unit (CCU) was established during the first five years of the Massachusetts ADRC and will continue during years 06 to 10. The three Units are at BAH, MGH, and UMMC. The overall goals of the CCU are to examine, diagnose, and enroll into the ADRC Patient Registry men and women with AD and related dementias , and health control subjects. An associated goal is to characterize the neurological, psychiatric, and neuropsychological features of AD across all stages of illness. The clinical experience at each Unit stimulates and supports new research initiatives, and enhances research productivity. In order to accomplish these goals, subjects are examined at one of the three clinical units; demographic and diagnostic information on all subjects are entered into the joint ADRC central Patient Registry. Standardized data are collected in each Unit on aspects of the clinical history of dementia, features of the neurological examination, results of cognitive tests, and laboratory diagnostic tests. These data are collected in a uniform manner at each of the three Units and maintained in separate but compatible databases. In order to track the course of illness, neurological and psychiatric examinations are repeated every six months; cognitive tests are performed every twelve months. Patients with AD are referred to specific research projects depending upon informed consent and the inclusion and exclusion criteria of each project. Patients with AD and control subjects are encouraged to sign a brain donation form indicating intent for postmortem examination.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005134-07
Application #
3809177
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Harvard University
Department
Type
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
Hopp, Sarah C; Lin, Yang; Oakley, Derek et al. (2018) The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer's disease. J Neuroinflammation 15:269
Xiong, Li; van Veluw, Susanne J; Bounemia, Narimene et al. (2018) Cerebral Cortical Microinfarcts on Magnetic Resonance Imaging and Their Association With Cognition in Cerebral Amyloid Angiopathy. Stroke 49:2330-2336
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Wegmann, Susanne; Eftekharzadeh, Bahareh; Tepper, Katharina et al. (2018) Tau protein liquid-liquid phase separation can initiate tau aggregation. EMBO J 37:
Racine, Annie M; Brickhouse, Michael; Wolk, David A et al. (2018) The personalized Alzheimer's disease cortical thickness index predicts likely pathology and clinical progression in mild cognitive impairment. Alzheimers Dement (Amst) 10:301-310
Bennett, Rachel E; Robbins, Ashley B; Hu, Miwei et al. (2018) Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer's disease. Proc Natl Acad Sci U S A 115:E1289-E1298
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872

Showing the most recent 10 out of 966 publications